Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25479660 | 1.00 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL23807290 | 0.94 | L3MBTL1 (0.46) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL25480285 | 0.90 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL23696167 | 0.90 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL25654374 | 0.88 | L3MBTL1 (0.40) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL23945646 | 0.87 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL23807007 | 0.86 | L3MBTL1 (0.41) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL25654319 | 0.85 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ATDP1GNAI3 | |
| SCHEMBL25122691 | 0.84 | TSHR (0.37) | EPHX2 | |
| SCHEMBL23945974 | 0.84 | L3MBTL1 (0.39) | L3MBTL1MEN1KMT2ATDP1GNAI3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885MEN1 4055/4885KMT2A 445/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | L3MBTL1 1394/4885MEN1 4055/4885KMT2A 445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.